JP2003511406A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2003511406A5 JP2003511406A5 JP2001529425A JP2001529425A JP2003511406A5 JP 2003511406 A5 JP2003511406 A5 JP 2003511406A5 JP 2001529425 A JP2001529425 A JP 2001529425A JP 2001529425 A JP2001529425 A JP 2001529425A JP 2003511406 A5 JP2003511406 A5 JP 2003511406A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- particle size
- average particle
- less
- effective average
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 description 52
- 239000002245 particle Substances 0.000 description 40
- 239000003795 chemical substances by application Substances 0.000 description 16
- 239000003814 drug Substances 0.000 description 12
- 229940079593 drugs Drugs 0.000 description 11
- 239000000126 substance Substances 0.000 description 10
- -1 anthelmintic Substances 0.000 description 7
- 239000002105 nanoparticle Substances 0.000 description 7
- 210000004209 Hair Anatomy 0.000 description 5
- 239000003381 stabilizer Substances 0.000 description 5
- 125000002091 cationic group Chemical group 0.000 description 4
- 239000000227 bioadhesive Substances 0.000 description 3
- LRFVTYWOQMYALW-UHFFFAOYSA-N Xanthine Chemical compound O=C1NC(=O)NC2=C1NC=N2 LRFVTYWOQMYALW-UHFFFAOYSA-N 0.000 description 2
- 230000000202 analgesic Effects 0.000 description 2
- 230000000749 insecticidal Effects 0.000 description 2
- 239000002917 insecticide Substances 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 229940005530 ANXIOLYTICS Drugs 0.000 description 1
- 206010000496 Acne Diseases 0.000 description 1
- 206010000565 Acquired immunodeficiency syndrome Diseases 0.000 description 1
- 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 229960000686 Benzalkonium Chloride Drugs 0.000 description 1
- 210000000988 Bone and Bones Anatomy 0.000 description 1
- 206010006451 Bronchitis Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- ABLZXFCXXLZCGV-UHFFFAOYSA-L CHEBI:8154 Chemical class [O-]P([O-])=O ABLZXFCXXLZCGV-UHFFFAOYSA-L 0.000 description 1
- 229960004015 Calcitonin Drugs 0.000 description 1
- 102400000113 Calcitonin Human genes 0.000 description 1
- 108060001064 Calcitonin Proteins 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 229920002101 Chitin Polymers 0.000 description 1
- DJHJJVWPFGHIPH-OODMECLYSA-N Chitin Chemical compound O[C@@H]1C(NC(=O)C)[C@H](O)OC(CO)[C@H]1COC[C@H]1C(NC(C)=O)[C@@H](O)[C@H](COC[C@H]2C([C@@H](O)[C@H](O)C(CO)O2)NC(C)=O)C(CO)O1 DJHJJVWPFGHIPH-OODMECLYSA-N 0.000 description 1
- 208000007451 Chronic Bronchitis Diseases 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 210000001072 Colon Anatomy 0.000 description 1
- 229940039227 DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 229940030606 DIURETICS Drugs 0.000 description 1
- 229940052760 Dopamine agonists Drugs 0.000 description 1
- 206010014561 Emphysema Diseases 0.000 description 1
- 210000003746 Feathers Anatomy 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 210000004072 Lung Anatomy 0.000 description 1
- 229940035363 MUSCLE RELAXANTS Drugs 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 210000003097 Mucus Anatomy 0.000 description 1
- 229940083876 Muscle relaxants FOR TREATMENT OF HEMORRHOIDS AND ANAL FISSURES FOR TOPICAL USE Drugs 0.000 description 1
- 210000000282 Nails Anatomy 0.000 description 1
- 229940074730 OPHTHAMOLOGIC DIAGNOSTIC AGENTS Drugs 0.000 description 1
- 229940005542 PARASYMPATHOMIMETICS Drugs 0.000 description 1
- 229940067631 Phospholipids Drugs 0.000 description 1
- 229940082622 Prostaglandin cardiac therapy preparations Drugs 0.000 description 1
- 229940077717 Prostaglandin drugs for peptic ulcer and gastro-oesophageal reflux disease (GORD) Drugs 0.000 description 1
- 206010038683 Respiratory disease Diseases 0.000 description 1
- 210000003491 Skin Anatomy 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- 210000001685 Thyroid Gland Anatomy 0.000 description 1
- 210000000515 Tooth Anatomy 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- 229940088594 Vitamin Drugs 0.000 description 1
- BZSJQMAZLOWECR-UHFFFAOYSA-N [Br-].C[NH+](C)C.C(C(=C)C)(=O)[O-].C[NH+](C)C Chemical compound [Br-].C[NH+](C)C.C(C(=C)C)(=O)[O-].C[NH+](C)C BZSJQMAZLOWECR-UHFFFAOYSA-N 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000003741 agents affecting lipid metabolism Substances 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 230000000507 anthelmentic Effects 0.000 description 1
- 230000003288 anthiarrhythmic Effects 0.000 description 1
- 230000003266 anti-allergic Effects 0.000 description 1
- 230000001396 anti-anti-diuretic Effects 0.000 description 1
- 230000002429 anti-coagulation Effects 0.000 description 1
- 230000001430 anti-depressive Effects 0.000 description 1
- 230000003178 anti-diabetic Effects 0.000 description 1
- 230000003474 anti-emetic Effects 0.000 description 1
- 230000000843 anti-fungal Effects 0.000 description 1
- 230000001387 anti-histamine Effects 0.000 description 1
- 230000003276 anti-hypertensive Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000001022 anti-muscarinic Effects 0.000 description 1
- 230000001355 anti-mycobacterial Effects 0.000 description 1
- 230000003579 anti-obesity Effects 0.000 description 1
- 230000002921 anti-spasmodic Effects 0.000 description 1
- 230000003208 anti-thyroid Effects 0.000 description 1
- 230000000259 anti-tumor Effects 0.000 description 1
- 230000000840 anti-viral Effects 0.000 description 1
- 239000003416 antiarrhythmic agent Substances 0.000 description 1
- 239000003146 anticoagulant agent Substances 0.000 description 1
- 239000000935 antidepressant agent Substances 0.000 description 1
- 239000003472 antidiabetic agent Substances 0.000 description 1
- 239000002111 antiemetic agent Substances 0.000 description 1
- 229940006131 antiglaucoma preparations and miotics Parasympathomimetics Drugs 0.000 description 1
- 239000000739 antihistaminic agent Substances 0.000 description 1
- 239000003926 antimycobacterial agent Substances 0.000 description 1
- 239000003434 antitussive agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 229940121357 antivirals Drugs 0.000 description 1
- 230000000949 anxiolytic Effects 0.000 description 1
- 239000002249 anxiolytic agent Substances 0.000 description 1
- 239000002830 appetite depressant Substances 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 102000012740 beta Adrenergic Receptors Human genes 0.000 description 1
- 108010079452 beta Adrenergic Receptors Proteins 0.000 description 1
- 230000003115 biocidal Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000010836 blood and blood product Substances 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- BBBFJLBPOGFECG-VJVYQDLKSA-N calcitonin Chemical compound N([C@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(N)=O)C(C)C)C(=O)[C@@H]1CSSC[C@H](N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1 BBBFJLBPOGFECG-VJVYQDLKSA-N 0.000 description 1
- 230000000271 cardiovascular Effects 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 201000003883 cystic fibrosis Diseases 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- 201000009910 diseases by infectious agent Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 239000003136 dopamine receptor stimulating agent Substances 0.000 description 1
- 239000003602 elastase inhibitor Substances 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000000855 fungicidal Effects 0.000 description 1
- 239000000417 fungicide Substances 0.000 description 1
- 150000004676 glycans Polymers 0.000 description 1
- 239000003163 gonadal steroid hormone Substances 0.000 description 1
- 230000000025 haemostatic Effects 0.000 description 1
- 239000000118 hair dye Substances 0.000 description 1
- 239000008266 hair spray Substances 0.000 description 1
- 230000002363 herbicidal Effects 0.000 description 1
- 239000004009 herbicide Substances 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 239000000677 immunologic agent Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000000297 inotrophic Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 239000003158 myorelaxant agent Substances 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 229940005943 ophthalmologic Antivirals Drugs 0.000 description 1
- 210000000056 organs Anatomy 0.000 description 1
- 229940094443 oxytocics Prostaglandins Drugs 0.000 description 1
- 230000001499 parasympathomimetic Effects 0.000 description 1
- 239000000734 parasympathomimetic agent Substances 0.000 description 1
- 230000000849 parathyroid Effects 0.000 description 1
- 239000000546 pharmaceutic aid Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000005648 plant growth regulator Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920000642 polymer Polymers 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012217 radiopharmaceutical Substances 0.000 description 1
- 230000002799 radiopharmaceutical Effects 0.000 description 1
- 238000000638 solvent extraction Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 230000000475 sunscreen Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001975 sympathomimetic Effects 0.000 description 1
- 210000001519 tissues Anatomy 0.000 description 1
- 230000000699 topical Effects 0.000 description 1
- 229940026754 topical Antivirals Drugs 0.000 description 1
- 201000008827 tuberculosis Diseases 0.000 description 1
- 230000000261 vasodilator Effects 0.000 description 1
- 239000003071 vasodilator agent Substances 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 229930003231 vitamins Natural products 0.000 description 1
- 229940075420 xanthine Drugs 0.000 description 1
Description
【特許請求の範囲】
【請求項1】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、ナノ粒子組成物が生物学的表面に吸着し、そしてナノ粒子組成物が、溶媒抽出または溶媒沈澱から生じる溶媒残渣を含有しない組成物。
【請求項2】 活性作用物質が貧水溶性活性作用物質および水溶性活性作用物質から成る群から選択される請求項1記載の組成物。
【請求項3】 活性作用物質が、薬剤、ビタミン、ハーブ、化粧剤、着色剤、風味剤、芳香剤、日焼止め剤、モイスチャライザー、防臭剤、食品、ヘアコンディショナー、毛染め剤、ヘアスプレー剤、美髪剤、毛髪浄化剤、脱毛剤、殺昆虫剤、肥料、殺虫剤、除草剤、殺菌剤および植物成長調節剤から成る群から選択される請求項1記載の組成物。
【請求項4】 薬剤が、タンパク質、ペプチド、nutriceuticals、肥満防止薬、コルチコステロイド、エラスターゼ阻害剤、鎮痛薬、抗真菌薬、腫瘍学治療薬、制吐薬、鎮痛薬、心臓血管薬、抗炎症薬、駆虫薬、抗不整脈薬、抗生物質、抗血液凝固薬、抗鬱薬、抗糖尿病薬、鎮痙薬、抗ヒスタミン薬、抗高血圧薬、抗ムスカリン薬、抗マイコバクテリウム薬、抗腫瘍薬、免疫抑制薬、抗甲状腺薬、抗ウイルス薬、抗不安鎮静薬、収斂薬、β−アドレナリン受容体遮断薬、血液産物および代用血液、強心薬、造影剤、咳抑制薬、診断薬、診断画像形成剤、利尿薬、ドーパミン作動薬、止血薬、免疫学的作用物質、脂質調節薬、筋弛緩薬、副交感神経様作動薬、上皮小体カルシトニンおよびビホスホネート、プロスタグランジン、放射性薬品、性ホルモン、抗アレルギー薬、刺激薬および食欲抑制薬、交感神経様作動薬、甲状腺薬、血管拡張薬、キサンチン、ざ瘡薬、α−ヒドロキシ処方物、嚢胞性繊維症治療薬、喘息治療薬、気腫治療薬、呼吸窮迫症候群治療薬、慢性気管支炎治療薬、慢性閉塞性肺疾患治療薬、臓器移植拒絶治療薬、結核および肺のその他の感染症のための治療薬、ならびに後天性免疫不全症候群に関連した呼吸器疾患治療薬から成る群から選択される請求項3記載の組成物。
【請求項5】 膣、眼、鼻、頬、口、結腸、局所および皮下投与から成る群から選択される投与のために処方される請求項1記載の組成物。
【請求項6】 少なくとも1つの陽イオン性表面安定剤がポリマー、バイオポリマー、多糖、セルロース系物質、アルギン酸塩、非ポリマー化合物およびリン脂質から成る群から選択される請求項1記載の組成物。
【請求項7】 表面安定剤がベンズアルコニウムクロリド、ポリメチルメタクリレートトリメチルアンモニウムブロミド、ポリビニルピロリドン−2−ジメチルアミノエチルメタクリレートジメチルスルフェートおよびヘキサデシルトリメチルアンモニウムブロミドから成る群から選択される請求項1記載の組成物。
【請求項8】 作用物質粒子の有効平均粒子サイズが約3500 nm未満である請求項1記載の組成物。
【請求項9】 1つまたはそれ以上の製薬上許容可能な賦形剤をさらに含む請求項1記載の組成物。
【請求項10】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ここで、活性作用物質粒子が組成物の総重量を基礎にして約99.99〜0.01(w/w)の量で存在し、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、そしてナノ粒子組成物が生物学的表面に吸着する組成物。
【請求項11】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ここで、表面安定剤が組成物の総重量を基礎にして約0.001〜約99.999%(w/w)の量で存在し、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、そしてナノ粒子組成物が生物学的表面に吸着する組成物。
【請求項12】 昆虫、歯、骨、爪、キチン質、羽、板状鱗屑、粘液、皮膚、毛髪および植物組織から成る群から選択される生物学的表面に吸着する請求項1記載の組成物。
【請求項13】 乾燥粉末形態の請求項1記載の組成物。
【請求項14】 作用物質粒子の有効平均粒子サイズが約3000 nm未満である請求項1記載の組成物。
【請求項15】 作用物質粒子の有効平均粒子サイズが約2500 nm未満である請求項1記載の組成物。
【請求項16】 作用物質粒子の有効平均粒子サイズが約2000 nm未満である請求項1記載の組成物。
【請求項17】 作用物質粒子の有効平均粒子サイズが約1500 nm未満である請求項1記載の組成物。
【請求項18】 作用物質粒子の有効平均粒子サイズが約1000 nm未満である請求項1記載の組成物。
【請求項19】 作用物質粒子の有効平均粒子サイズが約800 nm未満である請求項1記載の組成物。
【請求項20】 作用物質粒子の有効平均粒子サイズが約700 nm未満である請求項1記載の組成物。
【請求項21】 作用物質粒子の有効平均粒子サイズが約600 nm未満である請求項1記載の組成物。
【請求項22】 作用物質粒子の有効平均粒子サイズが約400 nm未満である請求項1記載の組成物。
【請求項23】 作用物質粒子の有効平均粒子サイズが約300 nm未満である請求項1記載の組成物。
【請求項24】 作用物質粒子の有効平均粒子サイズが約250 nm未満である請求項1記載の組成物。
【請求項25】 作用物質粒子の有効平均粒子サイズが約200 nm未満である請求項1記載の組成物。
【請求項26】 作用物質粒子の有効平均粒子サイズが約100 nm未満である請求項1記載の組成物。
【請求項27】 作用物質粒子の有効平均粒子サイズが約50 nm未満である請求項1記載の組成物。
【請求項1】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、ナノ粒子組成物が生物学的表面に吸着し、そしてナノ粒子組成物が、溶媒抽出または溶媒沈澱から生じる溶媒残渣を含有しない組成物。
【請求項2】 活性作用物質が貧水溶性活性作用物質および水溶性活性作用物質から成る群から選択される請求項1記載の組成物。
【請求項3】 活性作用物質が、薬剤、ビタミン、ハーブ、化粧剤、着色剤、風味剤、芳香剤、日焼止め剤、モイスチャライザー、防臭剤、食品、ヘアコンディショナー、毛染め剤、ヘアスプレー剤、美髪剤、毛髪浄化剤、脱毛剤、殺昆虫剤、肥料、殺虫剤、除草剤、殺菌剤および植物成長調節剤から成る群から選択される請求項1記載の組成物。
【請求項4】 薬剤が、タンパク質、ペプチド、nutriceuticals、肥満防止薬、コルチコステロイド、エラスターゼ阻害剤、鎮痛薬、抗真菌薬、腫瘍学治療薬、制吐薬、鎮痛薬、心臓血管薬、抗炎症薬、駆虫薬、抗不整脈薬、抗生物質、抗血液凝固薬、抗鬱薬、抗糖尿病薬、鎮痙薬、抗ヒスタミン薬、抗高血圧薬、抗ムスカリン薬、抗マイコバクテリウム薬、抗腫瘍薬、免疫抑制薬、抗甲状腺薬、抗ウイルス薬、抗不安鎮静薬、収斂薬、β−アドレナリン受容体遮断薬、血液産物および代用血液、強心薬、造影剤、咳抑制薬、診断薬、診断画像形成剤、利尿薬、ドーパミン作動薬、止血薬、免疫学的作用物質、脂質調節薬、筋弛緩薬、副交感神経様作動薬、上皮小体カルシトニンおよびビホスホネート、プロスタグランジン、放射性薬品、性ホルモン、抗アレルギー薬、刺激薬および食欲抑制薬、交感神経様作動薬、甲状腺薬、血管拡張薬、キサンチン、ざ瘡薬、α−ヒドロキシ処方物、嚢胞性繊維症治療薬、喘息治療薬、気腫治療薬、呼吸窮迫症候群治療薬、慢性気管支炎治療薬、慢性閉塞性肺疾患治療薬、臓器移植拒絶治療薬、結核および肺のその他の感染症のための治療薬、ならびに後天性免疫不全症候群に関連した呼吸器疾患治療薬から成る群から選択される請求項3記載の組成物。
【請求項5】 膣、眼、鼻、頬、口、結腸、局所および皮下投与から成る群から選択される投与のために処方される請求項1記載の組成物。
【請求項6】 少なくとも1つの陽イオン性表面安定剤がポリマー、バイオポリマー、多糖、セルロース系物質、アルギン酸塩、非ポリマー化合物およびリン脂質から成る群から選択される請求項1記載の組成物。
【請求項7】 表面安定剤がベンズアルコニウムクロリド、ポリメチルメタクリレートトリメチルアンモニウムブロミド、ポリビニルピロリドン−2−ジメチルアミノエチルメタクリレートジメチルスルフェートおよびヘキサデシルトリメチルアンモニウムブロミドから成る群から選択される請求項1記載の組成物。
【請求項8】 作用物質粒子の有効平均粒子サイズが約3500 nm未満である請求項1記載の組成物。
【請求項9】 1つまたはそれ以上の製薬上許容可能な賦形剤をさらに含む請求項1記載の組成物。
【請求項10】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ここで、活性作用物質粒子が組成物の総重量を基礎にして約99.99〜0.01(w/w)の量で存在し、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、そしてナノ粒子組成物が生物学的表面に吸着する組成物。
【請求項11】 安定生体付着性ナノ粒子組成物であって、以下の:
(a)半結晶状態、非晶質状態、結晶および半結晶の混合物、結晶および非晶質の混合物、または結晶、半結晶および非晶質の混合物である活性作用物質粒子、ここで、表面安定剤が組成物の総重量を基礎にして約0.001〜約99.999%(w/w)の量で存在し、ならびに
(b)それらの表面に吸着される少なくとも1つの陽イオン性表面安定剤
を含む組成物であって、
活性作用物質粒子が約4000 nm未満の有効平均粒子サイズを有し、そしてナノ粒子組成物が生物学的表面に吸着する組成物。
【請求項12】 昆虫、歯、骨、爪、キチン質、羽、板状鱗屑、粘液、皮膚、毛髪および植物組織から成る群から選択される生物学的表面に吸着する請求項1記載の組成物。
【請求項13】 乾燥粉末形態の請求項1記載の組成物。
【請求項14】 作用物質粒子の有効平均粒子サイズが約3000 nm未満である請求項1記載の組成物。
【請求項15】 作用物質粒子の有効平均粒子サイズが約2500 nm未満である請求項1記載の組成物。
【請求項16】 作用物質粒子の有効平均粒子サイズが約2000 nm未満である請求項1記載の組成物。
【請求項17】 作用物質粒子の有効平均粒子サイズが約1500 nm未満である請求項1記載の組成物。
【請求項18】 作用物質粒子の有効平均粒子サイズが約1000 nm未満である請求項1記載の組成物。
【請求項19】 作用物質粒子の有効平均粒子サイズが約800 nm未満である請求項1記載の組成物。
【請求項20】 作用物質粒子の有効平均粒子サイズが約700 nm未満である請求項1記載の組成物。
【請求項21】 作用物質粒子の有効平均粒子サイズが約600 nm未満である請求項1記載の組成物。
【請求項22】 作用物質粒子の有効平均粒子サイズが約400 nm未満である請求項1記載の組成物。
【請求項23】 作用物質粒子の有効平均粒子サイズが約300 nm未満である請求項1記載の組成物。
【請求項24】 作用物質粒子の有効平均粒子サイズが約250 nm未満である請求項1記載の組成物。
【請求項25】 作用物質粒子の有効平均粒子サイズが約200 nm未満である請求項1記載の組成物。
【請求項26】 作用物質粒子の有効平均粒子サイズが約100 nm未満である請求項1記載の組成物。
【請求項27】 作用物質粒子の有効平均粒子サイズが約50 nm未満である請求項1記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/414,159 US6428814B1 (en) | 1999-10-08 | 1999-10-08 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US09/414,159 | 1999-10-08 | ||
PCT/US2000/027434 WO2001026635A2 (en) | 1999-10-08 | 2000-10-05 | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009135738A Division JP2010018604A (ja) | 1999-10-08 | 2009-06-05 | 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2003511406A JP2003511406A (ja) | 2003-03-25 |
JP2003511406A5 true JP2003511406A5 (ja) | 2008-12-18 |
JP4394324B2 JP4394324B2 (ja) | 2010-01-06 |
Family
ID=23640205
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001529425A Expired - Fee Related JP4394324B2 (ja) | 1999-10-08 | 2000-10-05 | 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物 |
JP2009135738A Pending JP2010018604A (ja) | 1999-10-08 | 2009-06-05 | 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009135738A Pending JP2010018604A (ja) | 1999-10-08 | 2009-06-05 | 陽イオン性表面安定剤を有する生体付着性ナノ粒子組成物 |
Country Status (8)
Country | Link |
---|---|
US (3) | US6428814B1 (ja) |
EP (1) | EP1217993B1 (ja) |
JP (2) | JP4394324B2 (ja) |
AT (1) | ATE293959T1 (ja) |
AU (1) | AU7993800A (ja) |
CA (1) | CA2386782C (ja) |
DE (1) | DE60019774T2 (ja) |
WO (1) | WO2001026635A2 (ja) |
Families Citing this family (210)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996025918A1 (en) * | 1995-02-24 | 1996-08-29 | Nanosystems L.L.C. | Aerosols containing nanoparticle dispersions |
US20050004049A1 (en) * | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US20080213378A1 (en) * | 1998-10-01 | 2008-09-04 | Elan Pharma International, Ltd. | Nanoparticulate statin formulations and novel statin combinations |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US20090297602A1 (en) * | 1998-11-02 | 2009-12-03 | Devane John G | Modified Release Loxoprofen Compositions |
PT1126826E (pt) | 1998-11-02 | 2008-11-25 | Elan Pharma Int Ltd | Composição de metilfenidato de libertação modificada multiparticulada |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US20040057977A1 (en) * | 1999-09-22 | 2004-03-25 | Ecolab Inc. | Water-based pest bait compositions having water-sensitive insecticides and methods of making and use thereof |
US7744855B2 (en) | 2000-06-27 | 2010-06-29 | Vectura Limited | Method of making particles for use in a pharmaceutical composition |
DE10043321B4 (de) * | 2000-08-24 | 2005-07-28 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung |
DE10053397A1 (de) * | 2000-10-20 | 2002-05-02 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20080241070A1 (en) * | 2000-09-21 | 2008-10-02 | Elan Pharma International Ltd. | Fenofibrate dosage forms |
US7998507B2 (en) * | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US7198795B2 (en) | 2000-09-21 | 2007-04-03 | Elan Pharma International Ltd. | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate of nanoparticulate active agent compositions |
US20030224058A1 (en) * | 2002-05-24 | 2003-12-04 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7276249B2 (en) * | 2002-05-24 | 2007-10-02 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
DE10064453A1 (de) * | 2000-12-16 | 2002-07-04 | Schering Ag | Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen |
US20050048126A1 (en) | 2000-12-22 | 2005-03-03 | Barrett Rabinow | Formulation to render an antimicrobial drug potent against organisms normally considered to be resistant to the drug |
US6884436B2 (en) * | 2000-12-22 | 2005-04-26 | Baxter International Inc. | Method for preparing submicron particle suspensions |
US6951656B2 (en) | 2000-12-22 | 2005-10-04 | Baxter International Inc. | Microprecipitation method for preparing submicron suspensions |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US7151139B2 (en) * | 2001-04-23 | 2006-12-19 | Massachusetts Institute Of Technology | Antimicrobial polymeric surfaces |
WO2002085542A1 (en) * | 2001-04-23 | 2002-10-31 | Massachusetts Institute Of Technology | Antimicrobial polymeric surfaces |
US9089407B2 (en) | 2001-04-23 | 2015-07-28 | Massachusetts Institute Of Technology | Antibacterial coatings that inhibit biofilm formation on implants |
US6976647B2 (en) * | 2001-06-05 | 2005-12-20 | Elan Pharma International, Limited | System and method for milling materials |
MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
US7758890B2 (en) | 2001-06-23 | 2010-07-20 | Lyotropic Therapeutics, Inc. | Treatment using dantrolene |
JP2004537401A (ja) | 2001-08-08 | 2004-12-16 | ブラウン ユニバーシティ リサーチ ファウンデーション | 疎水性薬物の微粉砕方法 |
US20030054042A1 (en) * | 2001-09-14 | 2003-03-20 | Elaine Liversidge | Stabilization of chemical compounds using nanoparticulate formulations |
US20030095928A1 (en) * | 2001-09-19 | 2003-05-22 | Elan Pharma International Limited | Nanoparticulate insulin |
US20060003012A9 (en) | 2001-09-26 | 2006-01-05 | Sean Brynjelsen | Preparation of submicron solid particle suspensions by sonication of multiphase systems |
AU2002337692B2 (en) | 2001-09-26 | 2007-09-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion and solvent or liquid phase removal |
DE60222160T2 (de) * | 2001-10-12 | 2008-06-12 | Elan Pharma International Ltd., Athlone | Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung |
JP2005513145A (ja) * | 2001-12-21 | 2005-05-12 | セラター テクノロジーズ インコーポレイテッド | 改変されたポリマー脂質送達ビヒクル |
US20040101566A1 (en) * | 2002-02-04 | 2004-05-27 | Elan Pharma International Limited | Novel benzoyl peroxide compositions |
AU2003210517A1 (en) | 2002-02-04 | 2003-09-02 | Elan Pharma International, Ltd. | Drug nanoparticles with lysozyme surface stabiliser |
EP1490030B2 (en) * | 2002-03-20 | 2010-07-14 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
JP2005526095A (ja) * | 2002-03-20 | 2005-09-02 | エラン ファーマ インターナショナル,リミティド | 脆砕性の低い急速溶解投与剤型 |
EP1800666A1 (en) * | 2002-03-20 | 2007-06-27 | Elan Pharma International Limited | Nanoparticulate compositions of angiogenesis inhibitors |
WO2003086354A1 (en) | 2002-04-12 | 2003-10-23 | Elan Pharma International Ltd. | Nanoparticulate megestrol formulations |
US7101576B2 (en) * | 2002-04-12 | 2006-09-05 | Elan Pharma International Limited | Nanoparticulate megestrol formulations |
US20100226989A1 (en) * | 2002-04-12 | 2010-09-09 | Elan Pharma International, Limited | Nanoparticulate megestrol formulations |
US20040105889A1 (en) * | 2002-12-03 | 2004-06-03 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US8501232B2 (en) * | 2002-04-23 | 2013-08-06 | Nanotherapeutics, Inc. | Process of forming and modifying particles and compositions produced thereby |
ATE419835T1 (de) * | 2002-05-06 | 2009-01-15 | Elan Pharma Int Ltd | Nystatin-nanopartikelzusammensetzungen |
US7989503B2 (en) * | 2002-05-22 | 2011-08-02 | Nihon Pharmaceutical Co., Ltd. | Smooth muscle peristole inhibitor |
US20070264348A1 (en) * | 2002-05-24 | 2007-11-15 | Elan Pharma International, Ltd. | Nanoparticulate fibrate formulations |
US7763278B2 (en) * | 2002-06-10 | 2010-07-27 | Elan Pharma International Ltd. | Nanoparticulate polycosanol formulations and novel polycosanol combinations |
EP1551457A1 (en) * | 2002-07-16 | 2005-07-13 | Elan Pharma International Limited | Liquid dosage compositions of stable nanoparticulate active agents |
DE60334924D1 (de) * | 2002-09-11 | 2010-12-23 | Elan Pharma Int Ltd | Anoteilchengrösse |
US20080220074A1 (en) * | 2002-10-04 | 2008-09-11 | Elan Corporation Plc | Gamma radiation sterilized nanoparticulate docetaxel compositions and methods of making same |
WO2004032980A1 (en) * | 2002-10-04 | 2004-04-22 | Elan Pharma International Limited | Gamma irradiation of solid nanoparticulate active agents |
WO2004032891A1 (en) * | 2002-10-10 | 2004-04-22 | Symrise Gmbh & Co. Kg | Perfume hair cosmetic composition |
CA2504610C (en) * | 2002-11-12 | 2012-02-21 | Elan Pharma International Ltd. | Fast-disintegrating solid dosage forms being not friable and comprising pullulan |
US20050095267A1 (en) * | 2002-12-04 | 2005-05-05 | Todd Campbell | Nanoparticle-based controlled release polymer coatings for medical implants |
WO2004058216A2 (en) * | 2002-12-17 | 2004-07-15 | Elan Pharma International Ltd. | Milling microgram quantities of nanoparticulate candidate compounds |
US7666410B2 (en) | 2002-12-20 | 2010-02-23 | Kimberly-Clark Worldwide, Inc. | Delivery system for functional compounds |
JP4469846B2 (ja) * | 2003-01-31 | 2010-06-02 | エラン ファーマ インターナショナル,リミティド | ナノ粒子状トピラメート製剤 |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
US8512727B2 (en) * | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20040178135A1 (en) * | 2003-03-13 | 2004-09-16 | Beplate Douglas K. | Filtering device incorporating nanoparticles |
US7812120B2 (en) | 2003-03-21 | 2010-10-12 | Par Pharmaceutical, Inc. | Nasal calcitonin formulations containing chlorobutanol |
WO2004087307A1 (fr) * | 2003-03-31 | 2004-10-14 | Boris Olegovich Maier | Produit a base de chitosane, son procede de preparation, procede de preparation de derives dudit produit a base de chitosane et compositions a base de ceux-ci. |
JP2007501683A (ja) * | 2003-05-22 | 2007-02-01 | エラン ファーマ インターナショナル リミテッド | γ線照射によるナノ粒子活性物質分散体の滅菌法 |
ES2390162T3 (es) * | 2003-06-30 | 2012-11-07 | Nihon Pharmaceutical Co., Ltd. | Método para preparar una emulsión de mentol estabilizada |
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
CA2534924A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
JP2007506678A (ja) * | 2003-09-23 | 2007-03-22 | アルコン,インコーポレイテッド | 注入のためのトリアムシノロンアセトアニドおよび酢酸アネコルタブの処方物 |
US7837663B2 (en) | 2003-10-16 | 2010-11-23 | Kimberly-Clark Worldwide, Inc. | Odor controlling article including a visual indicating device for monitoring odor absorption |
US7678367B2 (en) | 2003-10-16 | 2010-03-16 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified particles |
US7488520B2 (en) | 2003-10-16 | 2009-02-10 | Kimberly-Clark Worldwide, Inc. | High surface area material blends for odor reduction, articles utilizing such blends and methods of using same |
US7413550B2 (en) | 2003-10-16 | 2008-08-19 | Kimberly-Clark Worldwide, Inc. | Visual indicating device for bad breath |
US7754197B2 (en) | 2003-10-16 | 2010-07-13 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using coordinated polydentate compounds |
US7794737B2 (en) * | 2003-10-16 | 2010-09-14 | Kimberly-Clark Worldwide, Inc. | Odor absorbing extrudates |
US7879350B2 (en) | 2003-10-16 | 2011-02-01 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using colloidal nanoparticles |
US7438875B2 (en) | 2003-10-16 | 2008-10-21 | Kimberly-Clark Worldwide, Inc. | Method for reducing odor using metal-modified silica particles |
US7879360B2 (en) * | 2003-11-05 | 2011-02-01 | Elan Pharma International, Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
US7968122B2 (en) * | 2003-12-10 | 2011-06-28 | Adventrx Pharmaceuticals, Inc. | Anti-viral pharmaceutical compositions |
JP2007520555A (ja) * | 2004-02-05 | 2007-07-26 | バクスター・インターナショナル・インコーポレイテッド | 自己安定化剤の使用により調製された分散剤 |
WO2005102287A2 (en) * | 2004-04-22 | 2005-11-03 | Duocort Ab | Pharmaceutical compositions for acute glucocorticoid therapy |
US20050281775A1 (en) * | 2004-06-16 | 2005-12-22 | Carrington Stephen D | Mucoadhesive and bioadhesive polymers |
US20060013873A1 (en) * | 2004-07-16 | 2006-01-19 | Chih-Chiang Yang | Bioadhesive dosage form of steroids |
US20060083694A1 (en) | 2004-08-07 | 2006-04-20 | Cabot Corporation | Multi-component particles comprising inorganic nanoparticles distributed in an organic matrix and processes for making and using same |
WO2006083326A2 (en) * | 2004-08-07 | 2006-08-10 | Cabot Corporation | Gas dispersion manufacture of nanoparticulates and nanoparticulate-containing products and processing thereof |
US8252320B2 (en) | 2004-10-21 | 2012-08-28 | Durect Corporation | Transdermal delivery system for sufentanil |
ATE551995T1 (de) | 2004-10-21 | 2012-04-15 | Durect Corp | Transdermale abgabesysteme |
US9492400B2 (en) | 2004-11-04 | 2016-11-15 | Massachusetts Institute Of Technology | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
CA2587710C (en) * | 2004-11-16 | 2014-10-21 | Elan Pharma International Ltd. | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (uk) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Стабільна композиція з наночастинок ралоксифену гідрохлориду |
WO2006062875A1 (en) * | 2004-12-08 | 2006-06-15 | Merck & Co., Inc. | Ophthalmic nanoparticulate formulation of a cyclooxygenase-2 selective inhibitor |
MX2007007342A (es) * | 2004-12-15 | 2007-12-11 | Elan Pharma Int Ltd | Formulaciones de tacrolimus nanoparticuladas. |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
MX2007008240A (es) * | 2005-01-05 | 2008-03-24 | Dow Global Technologies Inc | Eficacia incrementada de fungicidas en papel y carton. |
KR20070118224A (ko) * | 2005-01-06 | 2007-12-14 | 엘란 파마 인터내셔널 리미티드 | 나노입자형 칸데사르탄 제제 |
EP1853234A2 (en) | 2005-02-15 | 2007-11-14 | Elan Pharma International Limited | Aerosol and injectable formulations of nanoparticulate benzodiazepine |
EP1848270B1 (en) | 2005-02-17 | 2014-05-21 | Abbott Laboratories | Transmucosal administration of drug compositions for treating and preventing disorders in animals |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
CN101175480A (zh) * | 2005-03-16 | 2008-05-07 | 伊兰制药国际有限公司 | 纳米微粒白三烯受体拮抗剂/皮质类固醇制剂 |
MX2007011495A (es) * | 2005-03-17 | 2007-12-06 | Elan Pharma Int Ltd | Composiciones de bifosfonato en nanoparticulas. |
EA200702049A1 (ru) * | 2005-03-23 | 2008-02-28 | Элан Фарма Интернэшнл Лтд. | Композиции наночастиц кортикостероидов с антигистаминами |
AU2006235478B2 (en) | 2005-04-12 | 2011-07-21 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
MX2007012778A (es) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Formulaciones de derivados de quinazolina nanoparticuladas. |
US20110064803A1 (en) * | 2005-05-10 | 2011-03-17 | Elan Pharma International Limited. | Nanoparticulate and controlled release compositions comprising vitamin k2 |
CN101212954A (zh) * | 2005-05-10 | 2008-07-02 | 伊兰制药国际有限公司 | 纳米粒氯吡格雷制剂 |
US20060286239A1 (en) * | 2005-05-20 | 2006-12-21 | Philip Morris Usa Inc. | Nanoscale materials |
BRPI0611075A2 (pt) * | 2005-06-03 | 2010-08-03 | Elan Pharma Int Ltd | formulações de acetaminofeno em nanopartìcula |
WO2006133045A1 (en) * | 2005-06-03 | 2006-12-14 | Elan Pharma International, Limited | Nanoparticulate benidipine compositions |
DE602006012671D1 (de) * | 2005-06-03 | 2010-04-15 | Elan Pharma Int Ltd | Nanoteilchenförmige imatinib-mesylat-formulierungen |
JP2009517485A (ja) | 2005-06-08 | 2009-04-30 | エラン・ファルマ・インターナショナル・リミテッド | セフジトレンを含むナノ粒子状および制御放出組成物 |
ATE446742T1 (de) * | 2005-06-09 | 2009-11-15 | Elan Pharma Int Ltd | Nanopartikuläre ebastinformulierungen |
CN101237868A (zh) * | 2005-06-13 | 2008-08-06 | 伊兰制药国际有限公司 | 纳米粒氯吡格雷和阿司匹林组合制剂 |
JP2008543862A (ja) * | 2005-06-15 | 2008-12-04 | エラン ファーマ インターナショナル リミテッド | ナノ粒子アゼルニジピン製剤 |
US20070015719A1 (en) * | 2005-07-07 | 2007-01-18 | Elan Pharma International Limited | Nanoparticulate clarithromycin formulations |
CA2622200A1 (en) * | 2005-09-13 | 2007-03-22 | Elan Pharma International, Limited | Nanoparticulate tadalafil formulations |
EP2279727A3 (en) | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
EP2957174A1 (en) * | 2005-10-25 | 2015-12-23 | Dow Global Technologies Llc | Antimicrobial composition and method |
US8679545B2 (en) | 2005-11-12 | 2014-03-25 | The Regents Of The University Of California | Topical corticosteroids for the treatment of inflammatory diseases of the gastrointestinal tract |
US8497258B2 (en) | 2005-11-12 | 2013-07-30 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8324192B2 (en) | 2005-11-12 | 2012-12-04 | The Regents Of The University Of California | Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract |
US8022054B2 (en) | 2005-11-28 | 2011-09-20 | Marinus Pharmaceuticals | Liquid ganaxolone formulations and methods for the making and use thereof |
US9267937B2 (en) | 2005-12-15 | 2016-02-23 | Massachusetts Institute Of Technology | System for screening particles |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
EP2007435B1 (en) | 2006-03-31 | 2019-12-18 | Massachusetts Institute Of Technology | System for targeted delivery of therapeutic agents |
US7977103B2 (en) | 2006-04-20 | 2011-07-12 | Kimberly-Clark Worldwide, Inc. | Method for detecting the onset of ovulation |
CA2652280C (en) * | 2006-05-15 | 2014-01-28 | Massachusetts Institute Of Technology | Polymers for functional particles |
SG170047A1 (en) * | 2006-05-30 | 2011-04-29 | Elan Pharma Int Ltd | Nanoparticulate posaconazole formulations |
WO2007146319A2 (en) * | 2006-06-13 | 2007-12-21 | Symphony Medical, Inc. | Methods and apparatus for using polymer-based beads and hydrogels for cardiac applications |
WO2007150030A2 (en) * | 2006-06-23 | 2007-12-27 | Massachusetts Institute Of Technology | Microfluidic synthesis of organic nanoparticles |
JP5508003B2 (ja) | 2006-06-30 | 2014-05-28 | アイスイティカ ピーティーワイ リミテッド | ナノ粒子状の形態における生物学的に活性な化合物の調製のための方法 |
TW200820991A (en) * | 2006-07-10 | 2008-05-16 | Elan Pharma Int Ltd | Nanoparticulate sorafenib formulations |
BRPI0714173A2 (pt) * | 2006-07-12 | 2012-12-25 | Elan Pharma Int Ltd | composiÇço nanoparticulada estÁvel,mÉtodos para preparar a composiÇço, para prevenir e/ou tratar estados de doenÇas, sintomas, sÍndromes e condiÇÕes do sistema nervoso central, para melhorar ou manter a biodisponibilidade de modafinil, e para tratar distérbio com base neurolàgica, composiÇço farmacÊutica, e forma de dosagem |
US20100144845A1 (en) * | 2006-08-04 | 2010-06-10 | Massachusetts Institute Of Technology | Oligonucleotide systems for targeted intracellular delivery |
US20100136072A1 (en) * | 2006-11-08 | 2010-06-03 | Massachusetts Institute Of Technology | Polymeric Coatings that Inactivate Viruses and Bacteria |
AU2007325628A1 (en) | 2006-11-28 | 2008-06-05 | Marinus Pharmaceuticals | Nanoparticulate formulations and methods for the making and use thereof |
WO2008065502A1 (en) * | 2006-11-29 | 2008-06-05 | Pfizer Products Inc. | Pharmaceutical compositions based on a) nanoparticles comprising enteric polymers and b) casein |
WO2008098165A2 (en) | 2007-02-09 | 2008-08-14 | Massachusetts Institute Of Technology | Oscillating cell culture bioreactor |
JP2010522207A (ja) * | 2007-03-23 | 2010-07-01 | エラン・ファルマ・インターナショナル・リミテッド | ガンマ照射滅菌ナノ粒子状ドセタキセル組成物および該組成物を作製するための方法 |
WO2008124632A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Amphiphilic compound assisted nanoparticles for targeted delivery |
WO2008124634A1 (en) * | 2007-04-04 | 2008-10-16 | Massachusetts Institute Of Technology | Polymer-encapsulated reverse micelles |
US20100119612A1 (en) * | 2007-04-17 | 2010-05-13 | Bend Research, Inc | Nanoparticles comprising non-crystalline drug |
US20080268140A1 (en) | 2007-04-26 | 2008-10-30 | Csd, Inc. | Temporary removable solvent based protective coating |
US8221574B2 (en) * | 2007-04-26 | 2012-07-17 | Csd, Llc | Top coating for indoor and outdoor temporary removable graphics and system and method for making, applying and removing such graphics |
US8703204B2 (en) * | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
WO2008135852A2 (en) * | 2007-05-03 | 2008-11-13 | Pfizer Products Inc. | Pharmaceutical compositions comprising nanoparticles and casein |
US8309129B2 (en) * | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US8530463B2 (en) * | 2007-05-07 | 2013-09-10 | Hale Biopharma Ventures Llc | Multimodal particulate formulations |
CA2723470C (en) * | 2007-05-07 | 2013-12-03 | Hale Biopharma Ventures, Llc | Nasal administration of benzodiazepines |
US8426467B2 (en) | 2007-05-22 | 2013-04-23 | Baxter International Inc. | Colored esmolol concentrate |
US8722736B2 (en) | 2007-05-22 | 2014-05-13 | Baxter International Inc. | Multi-dose concentrate esmolol with benzyl alcohol |
WO2008149230A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glycol succinate |
WO2008149192A2 (en) * | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US20100215747A1 (en) * | 2007-07-13 | 2010-08-26 | Corey Jay Bloom | Nanoparticles comprising ionizable, poorly water soluble cellulosic polymers |
GB0714223D0 (en) * | 2007-07-20 | 2007-08-29 | Fujifilm Mfg Europe Bv | Preparation of fine particles |
EP2178490B1 (en) * | 2007-07-25 | 2019-09-04 | 3M Innovative Properties Company | Film forming dental compositions |
EP2180873B1 (en) | 2007-07-25 | 2018-04-11 | 3M Innovative Properties Company | Therapeutic dental composition for use in the inhibition of biofilm formation in the oral cavity. |
JP2011500569A (ja) | 2007-10-12 | 2011-01-06 | マサチューセッツ インスティテュート オブ テクノロジー | ワクチンナノテクノロジー |
US20100216754A1 (en) * | 2007-11-13 | 2010-08-26 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090123551A1 (en) * | 2007-11-13 | 2009-05-14 | Meritage Pharma, Inc. | Gastrointestinal delivery systems |
CN101969957A (zh) * | 2007-11-13 | 2011-02-09 | 梅里蒂奇制药公司 | 用于治疗胃肠道炎症的组合物 |
US20090131386A1 (en) * | 2007-11-13 | 2009-05-21 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
WO2009064458A2 (en) * | 2007-11-13 | 2009-05-22 | Meritage Pharma, Inc. | Compositions for the treatment of inflammation of the gastrointestinal tract |
US20090148491A1 (en) * | 2007-12-05 | 2009-06-11 | Abbott Cardiovascular Systems Inc. | Dual-Targeted Drug Carriers |
US9724362B2 (en) * | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US9233078B2 (en) * | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
KR20110007095A (ko) * | 2008-03-21 | 2011-01-21 | 엘란 파마 인터내셔널 리미티드 | 이마티니브의 부위-특이적 전달을 위한 조성물 및 사용방법 |
JP5613657B2 (ja) | 2008-03-28 | 2014-10-29 | ヘイル バイオファーマ ベンチャーズ,エルエルシー | ベンゾジアゼピン組成物の投与 |
US20090264392A1 (en) * | 2008-04-21 | 2009-10-22 | Meritage Pharma, Inc. | Treating eosinophilic esophagitis |
WO2009130704A1 (en) * | 2008-04-24 | 2009-10-29 | Technion Research And Development Foundation Ltd. | Beta-lactoglobulin-polysaccharide nanoparticles for hydrophobic bioactive compounds |
PL2291566T3 (pl) | 2008-06-06 | 2017-08-31 | Avery Dennison Corporation | Tymczasowa folia graficzna do stosowania na zewnątrz |
TWI580441B (zh) * | 2008-09-19 | 2017-05-01 | 愛爾康研究有限公司 | 穩定的藥學次微米懸浮液及其形成方法 |
US8343497B2 (en) | 2008-10-12 | 2013-01-01 | The Brigham And Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
US8343498B2 (en) | 2008-10-12 | 2013-01-01 | Massachusetts Institute Of Technology | Adjuvant incorporation in immunonanotherapeutics |
US8591905B2 (en) | 2008-10-12 | 2013-11-26 | The Brigham And Women's Hospital, Inc. | Nicotine immunonanotherapeutics |
US8277812B2 (en) | 2008-10-12 | 2012-10-02 | Massachusetts Institute Of Technology | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
EP2448406B1 (en) | 2009-02-26 | 2016-04-20 | Relmada Therapeutics, Inc. | Extended release oral pharmaceutical compositions of 3-hydroxy-n-methylmorphinan and method of use |
BRPI1014275B8 (pt) | 2009-04-24 | 2021-05-25 | Iceutica Pty Ltd | composição que compreende partículas de indometacina dispersas em pelo menos dois materiais de moagem parcialmente moídos |
FR2945950A1 (fr) | 2009-05-27 | 2010-12-03 | Elan Pharma Int Ltd | Compositions de nanoparticules anticancereuses et procedes pour les preparer |
HUE032426T2 (en) | 2009-05-27 | 2017-09-28 | Alkermes Pharma Ireland Ltd | Inhibition of flake aggregation in nanoparticulate meloxicam formulations |
US8709455B2 (en) | 2009-06-15 | 2014-04-29 | Chemyunion Quimica Ltda. | Sericin cationic nanoparticles for application in products for hair and dyed hair |
AU2010261510A1 (en) | 2009-06-19 | 2012-02-09 | Nanoform Hungary Ltd. | Nanostructured Sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
UA109772C2 (uk) * | 2009-07-02 | 2015-10-12 | Агент для підвищення гідрофільності ґрунту і способи його застосування | |
US9186324B2 (en) * | 2010-02-07 | 2015-11-17 | J.P.M.E.D. Ltd. | Hair follicle targeting compositions |
US9012511B2 (en) | 2010-05-19 | 2015-04-21 | Alkermes Pharma Ireland Limited | Nanoparticulate cinacalcet compositions |
GB201011905D0 (en) * | 2010-07-15 | 2010-09-01 | Unilever Plc | Benefit delivery particle,process for preparing said particle,compositions comprising said particles and a method for treating substrates |
US9005664B2 (en) * | 2010-10-17 | 2015-04-14 | Technion Research And Development Foundation Ltd. | Denatured lactoglobulin and polyphenol coassemblies |
CA2834212C (en) | 2011-04-29 | 2019-05-14 | Massachusetts Institute Of Technology | Layer processing for pharmaceuticals |
CN107737100A (zh) | 2011-06-14 | 2018-02-27 | 哈尔生物药投资有限责任公司 | 苯二氮卓组合物的投与 |
EP2785310B1 (en) | 2011-11-30 | 2017-10-25 | Fundació Institut de Ciències Fotòniques | Method for enhanced photoepilation based on metallic nano-complexes |
US9408419B2 (en) | 2012-03-23 | 2016-08-09 | Victoria's Secret Store Brand Management, Inc. | Moisturizing fabric material, use thereof in moisturizing bras, and method of manufacture |
US20130295143A1 (en) * | 2012-05-02 | 2013-11-07 | Massachusetts Institute Of Technology | Electroprocessing of active pharmaceutical ingredients |
US9334200B2 (en) | 2013-01-28 | 2016-05-10 | Bfp Management, Llc | Fertilizer composition and method for suspending fertilizer in an aqueous solution |
MX2015013845A (es) | 2013-04-01 | 2016-05-09 | Pulmatrix Inc | Polvos secos de tiotropio. |
JP2015209380A (ja) | 2014-04-24 | 2015-11-24 | ロレアル | 化粧用組成物 |
US10213960B2 (en) | 2014-05-20 | 2019-02-26 | Massachusetts Institute Of Technology | Plasticity induced bonding |
US9526734B2 (en) | 2014-06-09 | 2016-12-27 | Iceutica Pty Ltd. | Formulation of meloxicam |
MX2017013956A (es) | 2015-05-01 | 2018-09-05 | Cocrystal Pharma Inc | Analogos de nucleosidos para el tratamiento de la familia de virus flaviviridae y cancer. |
BR112018007986A2 (pt) * | 2015-10-21 | 2020-02-18 | Poznan Univ Of Medical Sciences | detecção e tratamento de cáries e microcavidades com nanopartículas |
WO2018031748A1 (en) | 2016-08-11 | 2018-02-15 | Ovid Therapeutics Inc. | Methods and compositions for treatment of epileptic disorders |
US10391105B2 (en) | 2016-09-09 | 2019-08-27 | Marinus Pharmaceuticals Inc. | Methods of treating certain depressive disorders and delirium tremens |
JP2020528408A (ja) * | 2017-07-19 | 2020-09-24 | デンツプライ シロナ インコーポレイテッド | 水溶性ヒドロゲル系歯科用組成物ならびにその調製および使用方法 |
WO2020118142A1 (en) | 2018-12-07 | 2020-06-11 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in prophylaxis and treatment of pospartum depression |
MX2022001553A (es) | 2019-08-05 | 2022-04-18 | Marinus Pharmaceuticals Inc | Ganaxolona para su uso en el tratamiento del estado epileptico. |
IL292487A (en) | 2019-11-01 | 2022-06-01 | Aquestive Therapeutics Inc | Compositions of medicinal meters and methods of treatment |
CA3159389A1 (en) | 2019-11-14 | 2021-05-20 | Aquestive Therapeutics, Inc. | Multimodal compositions and methods of treatment |
WO2021113834A1 (en) | 2019-12-06 | 2021-06-10 | Marinus Pharmaceuticals, Inc. | Ganaxolone for use in treating tuberous sclerosis complex |
US20220233471A1 (en) | 2021-01-15 | 2022-07-28 | Aquestive Therapeutics, Inc. | Prodrug compositions and methods of treatment |
Family Cites Families (104)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3013839A1 (de) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | Verfahren zur herstellung einer aktivierten pharmazeutischen zusammensetzung |
ZA822995B (en) | 1981-05-21 | 1983-12-28 | Wyeth John & Brother Ltd | Slow release pharmaceutical composition |
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4757059A (en) | 1984-08-14 | 1988-07-12 | International Copper Research Association | Method for treating convulsions and epilepsy with organic copper compounds |
US4663364A (en) | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
US4783484A (en) | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
JPS62185013A (ja) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | 易吸収性医薬組成物 |
DE3620685A1 (de) | 1986-06-20 | 1987-12-23 | Henkel Kgaa | Neue mittel zur abdeckung unverletzter und/oder verletzter bereiche menschlicher oder tierischer haut |
EP0262560A3 (en) | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl urea compound |
EP0264904A3 (en) | 1986-10-23 | 1988-08-17 | Ishihara Sangyo Kaisha, Ltd. | Pharmaceutical compositions containing benzoyl urea derivatives |
FR2634397B2 (fr) | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
FR2608988B1 (fr) | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanoparticules |
FR2608942B1 (fr) * | 1986-12-31 | 1991-01-11 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une substance, sous forme de nanocapsules |
DE3883918T2 (de) | 1987-11-03 | 1994-01-20 | Ilford Ltd | Vorrichtung zur Herstellung geänderter Abdrucke. |
US5719197A (en) | 1988-03-04 | 1998-02-17 | Noven Pharmaceuticals, Inc. | Compositions and methods for topical administration of pharmaceutically active agents |
JP2661709B2 (ja) | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | 高活性な農薬水和剤の製法 |
US5338761A (en) * | 1988-09-29 | 1994-08-16 | Shiseido Company Ltd. | Emulsified composition |
JPH02196719A (ja) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | 粉末状医薬組成物 |
US5750134A (en) * | 1989-11-03 | 1998-05-12 | Riker Laboratories, Inc. | Bioadhesive composition and patch |
WO1991010653A1 (en) | 1990-01-11 | 1991-07-25 | E.I. Du Pont De Nemours And Company | Herbicidal pyrimidines and triazines |
US5156767A (en) | 1990-01-16 | 1992-10-20 | Conoco Inc. | Emulsion breaking using alkylphenol-polyethylene oxide-acrylate polymer coated coalescer material |
HU212435B (en) | 1990-06-07 | 1996-06-28 | Sandoz Ag | Herbicidal compositions containing substituted phthalides and heterocyclic phthalides as active ingredient and process for preparation of their active ingredients. |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
US5766635A (en) | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
AU2317592A (en) | 1991-07-05 | 1993-02-11 | University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
HU9203730D0 (en) | 1991-12-06 | 1993-03-29 | Sandoz Ag | Substituted phthalides and heterocyclic ones |
JPH07112936A (ja) | 1992-04-27 | 1995-05-02 | Philippe Perovich | 治療用成分、とくにアスピリンに基づく成分の製剤方法 |
JP3478828B2 (ja) | 1992-11-16 | 2003-12-15 | ザ、プロクター、エンド、ギャンブル、カンパニー | 改善された布帛外観用染料移動抑制剤を有する布帛柔軟化組成物 |
DK0669128T3 (da) | 1992-11-17 | 2000-06-19 | Yoshitomi Pharmaceutical | Sustained-release mikrosfære indeholdende antipsykotikum og fremgangsmåde til at fremstille samme |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
FR2698560B1 (fr) | 1992-11-30 | 1995-02-03 | Virbac Laboratoires | Principes actifs pulvérulents stabilisés, compositions les contenant, leur procédé d'obtention et leurs applications. |
US5298262A (en) | 1992-12-04 | 1994-03-29 | Sterling Winthrop Inc. | Use of ionic cloud point modifiers to prevent particle aggregation during sterilization |
US5346702A (en) | 1992-12-04 | 1994-09-13 | Sterling Winthrop Inc. | Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization |
US5302401A (en) | 1992-12-09 | 1994-04-12 | Sterling Winthrop Inc. | Method to reduce particle size growth during lyophilization |
US5336507A (en) | 1992-12-11 | 1994-08-09 | Sterling Winthrop Inc. | Use of charged phospholipids to reduce nanoparticle aggregation |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5326552A (en) | 1992-12-17 | 1994-07-05 | Sterling Winthrop Inc. | Formulations for nanoparticulate x-ray blood pool contrast agents using high molecular weight nonionic surfactants |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
DE4324396A1 (de) | 1993-07-21 | 1995-01-26 | Henkel Kgaa | Reinigungsmittel mit hohem Benetzungsvermögen |
US6177104B1 (en) | 1994-01-27 | 2001-01-23 | The Board Of Regents Of The University Of Oklahoma | Particulate support matrix for making a rapidly dissolving dosage form |
US5912219A (en) | 1994-02-03 | 1999-06-15 | The Procter & Gamble Company | Acidic cleaning compositions |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
BE1008307A3 (fr) | 1994-06-16 | 1996-04-02 | Europharmaceuticals Sa | Sel de nimesulide hydrosoluble, solution aqueuse le contenant, sa preparation et son utilisation. |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5707981A (en) | 1994-07-28 | 1998-01-13 | Psorial, L.L.C. | Synergistic pharmaceutical compositions |
CZ285638B6 (cs) | 1994-10-07 | 1999-10-13 | Eka Chemicals Ab | Částice obsahující peroxysloučeninu a prostředek, který je obsahuje |
US5935271A (en) | 1994-10-13 | 1999-08-10 | Procter & Gamble Company | Laundry detergent compositions containing lipolytic enzyme and amines |
US5466440A (en) * | 1994-12-30 | 1995-11-14 | Eastman Kodak Company | Formulations of oral gastrointestinal diagnostic X-ray contrast agents in combination with pharmaceutically acceptable clays |
US5662883A (en) | 1995-01-10 | 1997-09-02 | Nanosystems L.L.C. | Microprecipitation of micro-nanoparticulate pharmaceutical agents |
US5665331A (en) | 1995-01-10 | 1997-09-09 | Nanosystems L.L.C. | Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers |
US5853756A (en) | 1995-01-11 | 1998-12-29 | J. B. Chemicals & Pharmaceuticals Limited | Controlled release formulations of Ranitidine |
US5569448A (en) | 1995-01-24 | 1996-10-29 | Nano Systems L.L.C. | Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5503723A (en) | 1995-02-08 | 1996-04-02 | Eastman Kodak Company | Isolation of ultra small particles |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5593657A (en) | 1995-02-09 | 1997-01-14 | Nanosystems L.L.C. | Barium salt formulations stabilized by non-ionic and anionic stabilizers |
US5591456A (en) | 1995-02-10 | 1997-01-07 | Nanosystems L.L.C. | Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer |
US5510118A (en) | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5580579A (en) | 1995-02-15 | 1996-12-03 | Nano Systems L.L.C. | Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5632996A (en) | 1995-04-14 | 1997-05-27 | Imaginative Research Associates, Inc. | Benzoyl peroxide and benzoate ester containing compositions suitable for contact with skin |
US6316022B1 (en) * | 1995-06-07 | 2001-11-13 | Noven Pharmaceuticals, Inc. | Transdermal compositions containing low molecular weight drugs which are liquid at room temperatures |
AU6742196A (en) | 1995-08-15 | 1997-03-12 | Novartis Ag | Pesticidal indazole derivatives |
US5827822A (en) | 1996-03-25 | 1998-10-27 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
US5932535A (en) | 1995-12-21 | 1999-08-03 | Henkel Kommanditgesellschaft Auf Aktien | Process for the production of light-colored, low-viscosity surfactant concentrates |
AU713849B2 (en) | 1995-12-27 | 1999-12-09 | Janssen Sciences Ireland Uc | Bioadhesive solid dosage form |
JP4107693B2 (ja) | 1996-02-09 | 2008-06-25 | 保土谷化学工業株式会社 | 固体粒子水性懸濁液の製造方法 |
KR970061942A (ko) | 1996-02-09 | 1997-09-12 | 무또 미노루 | 복합 입자 수성 현탁액 및 이의 제조 방법 |
US5935561A (en) | 1996-03-27 | 1999-08-10 | Procter & Gamble Company | Conditioning shampoo compositions containing select hair conditioning agents |
US5932202A (en) | 1996-03-27 | 1999-08-03 | The Procter & Gamble Company | Conditioning shampoo composition |
US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
PL187103B1 (pl) | 1996-06-07 | 2004-05-31 | Hercules Inc | Kompozycja pasty do zębów i sposób wytwarzania kompozycji pasty do zębów |
ES2188883T3 (es) | 1996-07-08 | 2003-07-01 | Ciba Sc Holding Ag | Derivados de triazina como filtro uv en productos antisolares. |
US6579352B1 (en) | 1996-07-25 | 2003-06-17 | Nikki-Universal Co., Ltd. | Air cleaning filter |
DE69734988T2 (de) | 1996-08-22 | 2006-09-21 | Jagotec Ag | Zubereitungen enthaltend mikropartikel von wasserunlöslichen stoffen und verfahren zu deren herstellung |
US5972389A (en) | 1996-09-19 | 1999-10-26 | Depomed, Inc. | Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter |
US5932404A (en) | 1996-12-18 | 1999-08-03 | Eastman Kodak Company | Silver halide photographic material containing a polymer with a photographically useful group which is rendered non-diffusible by cross-linking |
JPH10194996A (ja) | 1996-12-25 | 1998-07-28 | Janssen Pharmaceut Nv | アシル化シクロデキストリン含有製薬組成物 |
US6458373B1 (en) * | 1997-01-07 | 2002-10-01 | Sonus Pharmaceuticals, Inc. | Emulsion vehicle for poorly soluble drugs |
FR2758461A1 (fr) | 1997-01-17 | 1998-07-24 | Pharma Pass | Composition pharmaceutique presentant une biodisponibilite elevee et son procede de preparation |
GB9703552D0 (en) | 1997-02-20 | 1997-04-09 | Dow Corning | Polymerisation of cyclosiloxanes in the presence of fillers |
US20050004049A1 (en) | 1997-03-11 | 2005-01-06 | Elan Pharma International Limited | Novel griseofulvin compositions |
US5891420A (en) * | 1997-04-21 | 1999-04-06 | Aeropharm Technology Limited | Environmentally safe triancinolone acetonide aerosol formulations for oral inhalation |
CN1158071C (zh) | 1997-05-30 | 2004-07-21 | 渗透有限公司 | 多层渗透装置 |
IE970731A1 (en) | 1997-10-07 | 2000-10-04 | Fuisz Internat Ltd | Product and method for the treatment of hyperlipidemia |
US5929024A (en) | 1997-11-20 | 1999-07-27 | Colgate Palmolive Company | Cleaning compositions |
US5938017A (en) * | 1998-05-04 | 1999-08-17 | Wik; Dennis O. | Article for assisting persons to quit smoking and method for same |
JP4693238B2 (ja) * | 1998-06-19 | 2011-06-01 | オバン・エナジー・リミテッド | 水に溶けない化合物のサブミクロン粒子を生成させる方法 |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
EP2266542A3 (en) | 1998-10-01 | 2013-07-31 | Elan Pharma International Limited | Controlled release nanoparticulate compositions |
US6428814B1 (en) * | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6375986B1 (en) | 2000-09-21 | 2002-04-23 | Elan Pharma International Ltd. | Solid dose nanoparticulate compositions comprising a synergistic combination of a polymeric surface stabilizer and dioctyl sodium sulfosuccinate |
US5935921A (en) | 1999-01-26 | 1999-08-10 | Colgate-Palmolive Co. | Liquid descaling composition |
US5935272A (en) | 1999-02-02 | 1999-08-10 | Milliken & Company | Compositions comprising aryloxypolyoxyalkylene naphthalimide derivative colorants |
US6267989B1 (en) | 1999-03-08 | 2001-07-31 | Klan Pharma International Ltd. | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions |
ES2367352T3 (es) | 1999-04-28 | 2011-11-02 | Genetics Institute, Llc | Tratamiento de la fibrosis meidante el antagonismo de la il-3 y de las cadenas del receptor del il-3. |
US6656504B1 (en) | 1999-09-09 | 2003-12-02 | Elan Pharma International Ltd. | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US6316029B1 (en) | 2000-05-18 | 2001-11-13 | Flak Pharma International, Ltd. | Rapidly disintegrating solid oral dosage form |
KR100364496B1 (ko) * | 2000-07-14 | 2002-12-12 | 에쓰대시오일 주식회사 | 마이크로파를 이용한 폴리카보네이트 수지의 제조방법 |
CA2449490C (en) | 2001-06-05 | 2010-10-05 | Elan Pharma International Limited | System and method for milling materials |
US7112340B2 (en) | 2001-10-19 | 2006-09-26 | Baxter International Inc. | Compositions of and method for preparing stable particles in a frozen aqueous matrix |
JP4502318B2 (ja) | 2004-06-02 | 2010-07-14 | 河村電器産業株式会社 | 漏電遮断器 |
-
1999
- 1999-10-08 US US09/414,159 patent/US6428814B1/en not_active Expired - Fee Related
-
2000
- 2000-10-05 AU AU79938/00A patent/AU7993800A/en not_active Abandoned
- 2000-10-05 DE DE60019774T patent/DE60019774T2/de not_active Expired - Lifetime
- 2000-10-05 CA CA002386782A patent/CA2386782C/en not_active Expired - Fee Related
- 2000-10-05 WO PCT/US2000/027434 patent/WO2001026635A2/en active IP Right Grant
- 2000-10-05 JP JP2001529425A patent/JP4394324B2/ja not_active Expired - Fee Related
- 2000-10-05 AT AT00970579T patent/ATE293959T1/de not_active IP Right Cessation
- 2000-10-05 EP EP00970579A patent/EP1217993B1/en not_active Expired - Lifetime
-
2001
- 2001-12-07 US US10/004,808 patent/US7288267B2/en not_active Expired - Lifetime
-
2007
- 2007-09-11 US US11/898,274 patent/US7850995B2/en not_active Expired - Fee Related
-
2009
- 2009-06-05 JP JP2009135738A patent/JP2010018604A/ja active Pending
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2003511406A5 (ja) | ||
CA2386782A1 (en) | Bioadhesive nanoparticulate compositions having cationic surface stabilizers | |
DE69932144T2 (de) | Pulverförmige pernasale mittel | |
DE69629591T2 (de) | Formulierung zur intranasalen verabreichung | |
DE60120936T3 (de) | Behandlung von atemerkrankungen | |
DE60121570T2 (de) | Oral anzuwendende schnell zerfallende feste darreichungsformen | |
DE602004001209T3 (de) | Schnell wirkende pharmazeutische zusammensetzung | |
EP1296651B2 (en) | Method of making particles for use in a pharmaceutical composition | |
KR100234864B1 (ko) | 기도 및 폐질환을 치료하기 위한 모메타손푸로에이트 약제 | |
JPS61286321A (ja) | 口腔又は鼻腔用医薬組成物 | |
JP2003515551A5 (ja) | ||
JP5254618B2 (ja) | 経鼻投与用組成物 | |
AU7583491A (en) | Eriodictyon extract pharmaceutical compositions | |
DE69817774T2 (de) | Trägerstoff für trockenpulverinhalator, verfahren zu dessen herstellung und diesen enthaltende arzneimittel | |
AU685741B2 (en) | Sprayable analgesic composition and method of use | |
ES2266288T3 (es) | Pulverizador nasal tixotropico. | |
KR20030031997A (ko) | 살메테롤과 플루티카손 프로피오네이트의 약제학적포뮬레이션 | |
Pedersen et al. | Powder administration of pure budesonide for the treatment of seasonal allergic rhinitis | |
JP2005187328A (ja) | イブプロフェン含有解熱鎮痛組成物、及び感冒薬 | |
RU2608126C1 (ru) | Противовоспалительная композиция пролонгированного действия для лечения дыхательных путей | |
DE4420708A1 (de) | Entzündungshemmende Zusammensetzung zur Inhalation | |
US6515022B2 (en) | Use of inhaled retinoids in the treatment of lung diseases | |
EP1906920B1 (de) | Pharmazeutische zusammensetzung zur behandlung von xerostomie | |
CH667009A5 (de) | Bromocriptin enthaltende zusammensetzungen. | |
GB2420707A (en) | Compositions for intranasal administration |